Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis

Author(s)

Soares, Jaine L. S. ^[1] ; Oliveira, Enedina M. L. ^[2] ; Pontillo, Alessandra ^[1]

Affiliation

^[1] Univ Sao Paulo, Dept Imunol, Lab Imunogenet, ICB, Ave Prof Lineu Prestes 1730, Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo, Ambulatorio Doencas Desmielinizantes, Dept Neurol & Neurocirurgia, UNIFESP, Rua Pedro Toledo 650, Sao Paulo - Brazil

• Document type: Journal article
• Source: MULTIPLE SCLEROSIS AND RELATED DISORDERS; v. 29, p. 26-34, APR 2019.
• Web of Science Citations: 3

Abstract

Background: Multiple sclerosis (MS) is a neurodegenerative disease of central nervous system (CNS) with autoimmune and inflammatory characteristics, and a still uncertain pathogenesis. Early events as well as evolution of MS are heterogeneous (three main clinical forms) and multifactorial. Genome-wide association studies indicate that MS pathogenesis shares features with both autoimmune and inflammatory diseases. Innate immunity has been recently proved to be an important factor in MS. Genetic variants in inflammasome components have been associated with both autoimmune and neurodegenerative diseases, letting us hypothesize that inflammasome, and related cytokines IL-1 beta and IL-18, could represent important contributors in MS pathogenesis, and eventually explain, at least in part, the heterogeneity observed in MS patients. Aim: To evaluate the contribution of inflammasome in MS, in term of (a) genetic effect on development, severity and/or prognosis, and (b) complex activation in peripheral blood as a measure of systemic inflammation. Methods: Functional genetic variants in inflammasome components were analyzed in a cohort of MS patients, by the use of allele-specific assays and qPCR. Multivariate analysis was performed based on clinical form (recurrent remittent/RR, primary progressive/PP or secondary progressive/SP), severity index (EDSS) and progression index (PI), response to IFN-beta treatment. Peripheral blood monocytes (PBM) of patients were examined for inflammasome activation and expression profile. Results and discussion: Variants associated with low serum levels of IL-18 were significantly less frequent in MS patients than in controls, suggesting a protective role of diminished IL-18-mediate inflammation in MS development. On the other hands, gain-of-function variants in NLRP3 (Q705K) and IL1B (-511 C > T) associated with severity and progression of MS, suggesting that a constitutive activation of NLRP3 inflammasome could represent a risk factor for MS clinical presentation. Accordingly, -511C > T SNP resulted more frequent in progressive forms than in RR MS, reinforcing the idea that increased inflammasome activation characterized bad prognosis of MS. Altogether these findings corroborate previous data about the harmful role of NLRP3 inflammasome in experimental autoimmune encephalitis (EAE). Moreover, we reported for the first time the beneficial effect of NLRC4 rs479333 G > C variant in MS progression and in the response to IFN-beta treatment. This intronic polymorphism have been previously associated to decreased NLRC4 transcription and low IL-18 serum level, indicated once more that less activation of inflammasome and IL-18 production are beneficial for MS patients. PBM analysis showed that MS cells express higher level of inflammasome genes than HD ones, and are more prone to respond to a classical NLRP3 stimulus than HD. (AU)

• FAPESP's process: 15/23395-6 - Immunogenetics of the inflammasome and translational study "from bed to bench and back": analysis of variations in inflammasome genes in monogenic and multifactorial autoinflammatory diseases for differential diagnosis and therapeutic applications
• Grantee: Alessandra Pontillo
• Support Opportunities: Regular Research Grants
• FAPESP's process: 15/50650-7 - Characterization of novel molecular players in the control of obesity and obesity-induced inflammation
• Grantee: Alessandra Pontillo
• Support Opportunities: Regular Research Grants